Krakow

• An extension study to learn if Staccato Alprazolam is safe when treating long seizures in children ≥12 years of age and adults Recruiting
  2023-508868-30-00 5 2022-09-26 Treatment of stereotypical prolonged seizure
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult … Recruiting
  2024-510950-29-00 5 2022-07-21 Stereotypical prolonged seizure
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrom … Recruiting
  2024-515058-26-00 5 2021-12-17 NEPHROTIC SYNDROME
• A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to … Recruiting
  2022-502519-13-00 5 2021-05-07 Moderate to Severe Plaque Psoriasis
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting
  2023-506131-15-00 5 2019-09-10 Juvenile Idiopathic Arthritis
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended recruitment
  2024-515438-33-00 5 2026-01-12 Alopecia areata
• A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended recruitment
  2024-519469-23-00 4 2025-10-20 Severe Asthma
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended recruitment
  2024-519370-40-00 5 2025-07-16 Alopecia areata
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended recruitment
  2024-515494-95-00 4 2025-05-26 Moderate to Severe Atopic Dermatitis (AD)
• A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat … Ended recruitment
  2024-513348-27-00 5 2025-05-09 Plaque psoriasis
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t … Ended recruitment
  2024-512496-12-00 5 2025-04-01 Moderate to Severe Plaque Psoriasis
• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended recruitment
  2024-510719-31-00 5 2025-01-24 Moderate to Severe Vasomotor Symptoms (VMS)
• CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended recruitment
  2024-512720-11-00 5 2025-01-16 chronic venous ulcers (CVU)
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Ended recruitment
  2023-508817-18-00 5 2024-10-08 Perennial Allergic Rhinitis (PAR)
• A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended recruitment
  2023-508039-29-00 4 2024-09-16 Moderate-to-severe Asthma
• A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Ended recruitment
  2022-502570-16-01 4 2024-06-27 Treatment of patients with inadequately controlled moderate to severe
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo

Showing 73–96 of 186 trials